vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $180.9M, roughly 1.1× AVANOS MEDICAL, INC.). On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -6.0%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $2.6M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -7.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
AVNS vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $205.2M |
| Net Profit | $-1.3M | — |
| Gross Margin | 47.5% | 16.2% |
| Operating Margin | 1.4% | -14.4% |
| Net Margin | -0.7% | — |
| Revenue YoY | 0.7% | -6.0% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $205.2M | ||
| Q3 25 | $177.8M | $210.3M | ||
| Q2 25 | $175.0M | $228.0M | ||
| Q1 25 | $167.5M | $217.9M | ||
| Q4 24 | $179.6M | $218.2M | ||
| Q3 24 | $170.4M | $213.8M | ||
| Q2 24 | $171.7M | $237.1M | ||
| Q1 24 | $166.1M | $239.2M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $-9.4M | ||
| Q2 25 | $-76.8M | $-9.4M | ||
| Q1 25 | $6.6M | $-7.2M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $-7.1M | ||
| Q2 24 | $1.8M | $2.8M | ||
| Q1 24 | $-900.0K | $-6.1M |
| Q4 25 | 47.5% | 16.2% | ||
| Q3 25 | 48.4% | 20.3% | ||
| Q2 25 | 52.6% | 21.5% | ||
| Q1 25 | 53.6% | 21.2% | ||
| Q4 24 | 54.6% | 19.5% | ||
| Q3 24 | 54.5% | 20.8% | ||
| Q2 24 | 55.7% | 22.7% | ||
| Q1 24 | 57.1% | 20.2% |
| Q4 25 | 1.4% | -14.4% | ||
| Q3 25 | 0.1% | -1.6% | ||
| Q2 25 | -42.6% | -1.1% | ||
| Q1 25 | 6.1% | -1.5% | ||
| Q4 24 | -233.0% | -2.0% | ||
| Q3 24 | 7.0% | 0.1% | ||
| Q2 24 | 3.7% | 1.4% | ||
| Q1 24 | 2.4% | 0.1% |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | -4.5% | ||
| Q2 25 | -43.9% | -4.1% | ||
| Q1 25 | 3.9% | -3.3% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | -3.3% | ||
| Q2 24 | 1.0% | 1.2% | ||
| Q1 24 | -0.5% | -2.6% |
| Q4 25 | $-0.02 | $-2.76 | ||
| Q3 25 | $-0.03 | $-0.34 | ||
| Q2 25 | $-1.66 | $-0.34 | ||
| Q1 25 | $0.14 | $-0.26 | ||
| Q4 24 | $-8.64 | $-0.22 | ||
| Q3 24 | $0.09 | $-0.26 | ||
| Q2 24 | $0.04 | $0.10 | ||
| Q1 24 | $-0.02 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $66.3M |
| Total DebtLower is stronger | $90.3M | $180.9M |
| Stockholders' EquityBook value | $778.2M | $179.8M |
| Total Assets | $1.1B | $551.2M |
| Debt / EquityLower = less leverage | 0.12× | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $66.3M | ||
| Q3 25 | $70.5M | $54.0M | ||
| Q2 25 | $90.3M | $49.8M | ||
| Q1 25 | $97.0M | $79.1M | ||
| Q4 24 | $107.7M | $71.8M | ||
| Q3 24 | $89.0M | $54.1M | ||
| Q2 24 | $92.2M | $42.1M | ||
| Q1 24 | $75.8M | $48.4M |
| Q4 25 | $90.3M | $180.9M | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | $201.6M | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $179.8M | ||
| Q3 25 | $778.0M | $251.2M | ||
| Q2 25 | $776.3M | $260.5M | ||
| Q1 25 | $839.4M | $253.1M | ||
| Q4 24 | $828.5M | $245.3M | ||
| Q3 24 | $1.2B | $271.4M | ||
| Q2 24 | $1.2B | $270.5M | ||
| Q1 24 | $1.2B | $277.3M |
| Q4 25 | $1.1B | $551.2M | ||
| Q3 25 | $1.1B | $632.1M | ||
| Q2 25 | $1.0B | $639.4M | ||
| Q1 25 | $1.1B | $657.4M | ||
| Q4 24 | $1.2B | $621.6M | ||
| Q3 24 | $1.7B | $662.5M | ||
| Q2 24 | $1.7B | $666.7M | ||
| Q1 24 | $1.7B | $675.4M |
| Q4 25 | 0.12× | 1.01× | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | 0.82× | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $8.8M |
| Free Cash FlowOCF − Capex | $21.3M | $2.6M |
| FCF MarginFCF / Revenue | 11.8% | 1.3% |
| Capex IntensityCapex / Revenue | 3.8% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $8.8M | ||
| Q3 25 | $14.0M | $3.6M | ||
| Q2 25 | $6.8M | $10.7M | ||
| Q1 25 | $25.7M | $10.9M | ||
| Q4 24 | $57.9M | $19.2M | ||
| Q3 24 | $23.0M | $10.8M | ||
| Q2 24 | $27.8M | $8.7M | ||
| Q1 24 | $-8.0M | $9.1M |
| Q4 25 | $21.3M | $2.6M | ||
| Q3 25 | $7.0M | $-2.7M | ||
| Q2 25 | $-4.2M | $7.4M | ||
| Q1 25 | $19.0M | $4.8M | ||
| Q4 24 | $53.1M | $14.0M | ||
| Q3 24 | $20.0M | $4.6M | ||
| Q2 24 | $21.9M | $1.5M | ||
| Q1 24 | $-12.1M | $3.3M |
| Q4 25 | 11.8% | 1.3% | ||
| Q3 25 | 3.9% | -1.3% | ||
| Q2 25 | -2.4% | 3.3% | ||
| Q1 25 | 11.3% | 2.2% | ||
| Q4 24 | 29.6% | 6.4% | ||
| Q3 24 | 11.7% | 2.2% | ||
| Q2 24 | 12.8% | 0.6% | ||
| Q1 24 | -7.3% | 1.4% |
| Q4 25 | 3.8% | 3.0% | ||
| Q3 25 | 3.9% | 3.0% | ||
| Q2 25 | 6.3% | 1.4% | ||
| Q1 25 | 4.0% | 2.8% | ||
| Q4 24 | 2.7% | 2.4% | ||
| Q3 24 | 1.8% | 2.9% | ||
| Q2 24 | 3.4% | 3.0% | ||
| Q1 24 | 2.5% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | 3.11× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
